养血清脑颗粒对慢性脑供血不足病人认知功能及脑血流的影响

目的 观察养血清脑颗粒对慢性脑供血不足病人的认知功能改善及脑血流速度的影响。方法 将76例慢性脑供血不足病人随机分为治疗组和对照组，对照组口服复方丹参片，治疗组口服养血清脑颗粒，疗程为8周。观察两组临床症状疗效、脑血流的变化。结果 治疗组临床症状总有效率为78．9％，明显优于对照组的60．5％（P〈0．05）；TCD提示养血清脑颗粒治疗后脑血流均较治疗前有明显改善（P〈0．05）。结论 养血清脑颗粒治疗慢性脑供血不足安全有效。     

盐酸丁咯地尔联合养血清脑颗粒治疗慢性脑供血不足

目的观察盐酸丁咯地尔联合养血清脑颗粒治疗慢性脑供血不足（chronic cerebral circulation insrfficiency，CCCI）患者的临床疗效。方法选择我院72例慢性脑供血不足患者。随机分为治疗组和对照组。治疗组应用盐酸丁咯地尔注射液200mg加0．9％氯化钠溶液500ml，静滴，1次／d，同时口服养血清脑颗粒4～8g／次，对照组采用丹参注射液20ml加0．9％氯化钠溶液500ml，静滴1次／d，同时口服心脑康，2彬次，3次／d。其他对症治疗相同，疗程均为10d，观察两组患者的疗效。结果两组患者临床疗效间差异有非常显著性意义（P〈0．01），且无明显不良反应。结论盐酸丁咯地尔联合养血清脑颗粒治疗慢性脑供血不足优于一般治疗。     

养血清脑颗粒治疗椎-基底动脉供血不足42例

目的观察养血清脑颗粒治疗椎-基底动脉供血不足（VBI）的临床疗效。方法将84例VBI眩晕患者随机分为两组。治疗组采用养血清脑颗粒治疗,对照组采用复方丹参片治疗。结果治疗组总有效率为90．48％,对照组总有效率为69.05％。两组比较差异有统计学意义（P〈0.05）。结论养血清脑颗粒治疗椎-基底动脉供血不足疗效明显优于复方丹参片,且无严重不良反应。     

慢性脑供血不足血栓前状态标志物水平变化及用药干预后的影响

目的探讨慢性脑供血不足（CCCI）患者是否存在血栓前状态及药物干预对血栓前状态标志物水平的影响。方法根据日本2000年修订的CCCI诊断标准选择研究对象90例,将其分为基础治疗组（A组）、养血清脑颗粒组（B组）、联合用药组（C组）各30例,同时选正常对照组（D组）27名,用药前后测定一氧化氮（NO）、血管内皮素-1（ET-1）、纤维蛋白原（FIB）、Ⅰ型纤溶酶原激活物抑制物（PAI-1）及组织型纤溶酶原激活物（t-PA）水平。结果A组、B组、C组治疗前分别与D组比较,NO、t-PA水平降低,ET-1、PAI-1、FIB水平升高（P〈0.05或P〈0.01）;B组、C两组治疗后各检测指标水平较治疗前均有统计学意义（P〈0.01）。治疗后,B组、C组与A组各检测指标比较均有统计学意义（P〈0.05或P〈0.01）。结论CCCI患者存在血栓前状态,而养血清脑颗粒能改善血栓前状态的各指标。     

养血清脑颗粒联合西比灵治疗2型糖尿病合并慢性脑供血不足的效果分析

目的分析养血清脑颗粒联合西比灵治疗2型糖尿病合并慢性脑供血不足的效果方法选取2型糖尿病合并慢性脑供血不足患者共153例作为研究对象,随机分为3组,分别采用养血清脑颗粒联合西比灵治疗法、西比灵治疗法和养血清脑颗粒治疗法治疗,比较和分析3组患者的治疗前后血流速度变化和临床疗效。结果 3组患者治疗前后血流速度变化比较发现,治疗前后大前动脉、大中动脉、椎动脉和基层动脉的血流速度变化差异显著(P0.05);治疗后联合治疗组分别与西比灵治疗后和养血清脑颗粒治疗后比较,大前动脉、大中动脉、椎动脉和基层动脉的血流速度变化差异显著(P0.05);联合治疗后分别与西比灵治疗后和养血清脑颗粒治疗后的临床疗效比较发现,治愈、无效和总有效率差异显著(P0.05)。结论血清脑颗粒联合西比灵治疗2型糖尿病合并慢性脑供血不足能够有效改善动脉血流速度,提高临床治疗疗效,具有推广和应用价值。     

养血清脑颗粒治疗椎基底动脉供血不足性眩晕

目的观察养血清脑颗粒治疗椎基底动脉供血不足性眩晕的临床疗效。方法64例病人随机分为两组,大剂量组33例,口服养血清脑颗粒8g,3次/日;常规剂量组31例,口服养血清脑颗粒4g,3次/日。观察两组治疗前后症状、血液流变学指标的变化。结果大剂量组总有效率为96.97%优于常规剂量组的83.87%（P〈0.05）,在改善眩晕症状及血液流变学各项指标方面,大剂量组疗效优于常规剂量组,差异有统计学意义（P〈0.05或P〈0.01）。结论养血清脑颗粒对椎基底动脉供血不足性眩晕有显著疗效。     

头痛宁对慢性脑供血不足患者血浆LPA、AP水平的影响

目的探讨头痛宁治疗慢性脑供血不足的作用机制。方法将76例慢性脑供血不足患者随机分为观察组（40例）和对照组（36例）,两组均予常规治疗,观察组在此基础上口服头痛宁胶囊,观察两组治疗效果。测定治疗前后两组血浆LPA、AP水平,并与30例查体健康者（健康组）比较。结果观察组和对照组LPA、AP水平明显高于健康组（P〈0．05）。服用头痛宁胶囊后LPA、AP明显降低,与对照组相比P〈0．05。结论慢性脑供血不足患者血浆LPA、AP水平明显增高,头痛宁对慢性脑供血不足有一定治疗作用。     

缬沙坦联用养血清脑颗粒治疗原发性高血压60例疗效观察

目的观察缬沙坦联用养血清脑颗粒的降压疗效。方法选择原发性高血压患者118例,随机分为治疗组60例和对照组58例。对照组给予缬沙坦80mg／d,晨8时顿服;治疗组在此基础上给予养血清脑颗粒1包／次,3次／d;疗程均为4周。记录每日血压变化和自觉症状、不良反应。结果两组治疗前后收缩压、舒张压比较差异均有统计学意义（P均〈0．01）,治疗后两组血压比较差异有统计学意义（P〈0．05或〈0．01）。结论缬沙坦联用养血清脑颗粒治疗高血压疗效确切、安全,无明显不良反应。     

养血清脑颗粒治疗慢性脑供血不足的疗效观察

目的分析养血清脑颗粒治疗慢性脑供血不足的疗效,为相关临床治疗工作提供有效依据。方法选取我院2015年10月~2016年1月接受治疗的30例慢性脑供血不足患者为研究对象,将其随机分为对照组与观察组,各15例,在常规治疗的基础上,对照组患者给予尼莫地平片口服治疗,观察组患者给予养血清脑颗粒治疗,观察两组疗效及不良反应发生率,并进行对比。结果观察组总有效率为100%,对照组总有效率为66.67%,观察组总有效率明显高于对照组,差异有统计学意义(P0.05);两组患者均未出现不良反应。结论养血清脑颗粒治疗慢性脑供血不足的疗效显著,并且安全可靠,值得在治疗慢性脑供血不足患者中推广应用。     

慢性心力衰竭治疗中血浆脑钠肽的变化及其意义

目的：探讨慢性心力衰竭患者治疗中血浆脑钠肽水平的变化及其临床意义。方法：选择慢性心力衰竭患者63例，联合使用β受体阻滞剂及血管紧张素转换酶抑制剂治疗6月，于治疗前后分别测定血浆脑钠肽水平，并使用超声心动图仪检测左心室收缩功能及左心室结构。30名健康者为对照。结果：心力衰竭组血浆脑钠肽水平显著高于对照组（P〈0．001），并与心力衰竭严重程度有关；左心室射血分数显著低于对照组（P〈0．01）。心力衰竭患者血浆脑钠肽水平与心脏结构功能指标的直线相关分析表明，血浆脑钠肽水平与左心室射血分数呈负相关（r=-0．38，P〈0．05），心力衰竭患者有效治疗后，血浆脑钠肽水平显著下降（P〈0．05），左心室射血分数提高（P〈0．05）。结论：血浆脑钠肽水平可作为评价慢性心力衰竭治疗效果的客观指标。     

青少年高血压的研究进展

随着人们生活和行为方式的改变,高血压发病明显呈年轻化趋势。在青少年时期识别高血压病高危人群有助于早期进行有效干预和治疗,降低未来高血压的发生率及其严重性。现试从青少年高血压的诊断、发病因素、特点、治疗策略等方面的研究进展作一综述。     

Morbidity in cardiovascular diseases in immigrants in Sweden

INTRODUCTION: Although immigration to Sweden has increased in the last few decades, the incidence rates of cardiovascular disease and coronary heart disease in immigrants are unknown. The aim of the present study is to estimate whether place of birth affects the incidence rates of cardiovascular disease and coronary heart disease. MATERIAL AND METHODS: The study was designed as a follow-up study on morbidity in cardiovascular disease and coronary heart disease between 1 January 1997 and 31 December 1998, including three and a half million persons with age range 35-64 years, of whom 550 000 were born abroad, from the database MigMed consisting of the whole Swedish population. Incidence rates and relative risks were estimated by indirect standardization and a proportional hazard model. RESULTS: The age-adjusted risk of coronary heart disease was higher in most foreign-born groups than in Swedes. For example, in nine of 12 male groups, the relative risks varied between 1.1 and 2.2, and in seven of 12 female groups, the relative risks varied between 1.4 and 2.5. When also adjusting for level of education and employment status, the risks were still high, but on a lower level. CONCLUSIONS: Foreign-born people possess an over-risk of cardiovascular or coronary heart disease(CVD/CHD) compared with Swedish-born persons, also when level of education and employment status are taken into account.     

C·肉毒杀鼠素(冻干剂)应用研究

目的为研究C·肉毒杀鼠索对杀灭达乌尔黄鼠(简称黄鼠)的大面积应用情况和对家畜、家禽的毒害作用,进行了C·肉毒杀鼠素的应用研究.方法大面积投毒采用ES-2药饵撒播机[1],间隔约80m进行条投.羊、鸡采用直接灌胃.结果大面积应用的灭鼠率为83.72%.对羊、鸡最高剂量分别为500万MLD、150万MLD,均未出现中毒现象.结论 C·肉毒杀鼠素是较为理想的草原大面积杀灭黄鼠的理想、首选药物.     

Pulmonary sporotrichosis in Oklahoma in susceptibilities in vitro

Six cases of pulmonary sporotichosis were observed in 2 institutions in Oklahoma City, Okla. Three of the patients were treated with iodides with or without surgery. Although one patient required a second course of iodides, the patients have remained well after at least 34 months of follow-up. Three patients treated with amphotericin B, single course as well as multiple courses, and other antifungal agents (hydroxystilbamidine and miconazole) have all relapsed. These cases and a reviewed of more than 40 cases of pulmonary sporotrichosis susceptibilities of Sporothrix schenckii that we observed in vitro suggest that amphotericin B is not an effective agent for the treatment of pulmonary sporotrichosis. It is our opinion that the treatment of choice for pulmonary sporotrichosis is a supersaturated solution of potassium iodide. If the patient is allergic to the medication or fails to respond, then a combination of amphotericin B plus flucytosine may be tried.     

Differences in outcome in primary angioplasty in women.

BACKGROUND: In acute myocardial infarction (AMI), primary percutaneous transluminal coronary angioplasty (PTCA) has proved to be the best therapeutic approach. Several factors have been associated with worse outcome in AMI in females. Are there differences in outcome in women undergoing PTCA for AMI? AIM: To evaluate gender influence on clinical outcome and in-hospital mortality in patients with AMI who undergo primary percutaneous interventions. METHODS: We studied 245 consecutive patients (72 women, 29.4 %), who underwent primary PTCA between January 2000 and December 2001. The following parameters were analyzed: risk factors for coronary artery disease including hypertension, diabetes, smoking, hypercholesterolemia and family history, previous AMI, PTCA or angina, pain-to-balloon time, extent of coronary disease and outcome. RESULTS: Female patients were older (67.9+/-11.6 vs. 59.6+/-13; p < 0.001) with a higher prevalence of hypertension (65.3 % vs. 47.4 %; p < 0.05) and angina (29.0 % vs. 16.0 %; p < 0.05) and lower prevalence of smoking (27.8 % vs. 54.3 %; p < 0.001). Pain-to-balloon time was longer in women (6.8+/-4.1 vs. 5.4+/-3.7 hours; p < 0.05). Extent of coronary disease was similar in both groups. Glycoprotein IIb/IIIa inhibitors were used in 84.7 % of women and 90.8 % of men. The frequency of hemorrhagic complications (5.6 % vs. 5.2 %) and arrhythmias (15.3 % vs. 10.4%) and in-hospital mortality (9.7 6.4 %) were higher in females, although without statistical significance (p = NS). Hospitalization time was similar in both groups. CONCLUSIONS: Despite the growing awareness of a gender bias in therapeutic approaches to AMI, there are still some differences in outcome, with a trend towards higher mortality rates in women. Older age and longer pain-to-balloon time could account for this.